Compare Charter Communications Inc (CHTR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs Medpace Holdings Inc — how do they compare? Charter Communications Inc trades at $131.9 (market cap $15.73B), while Medpace Holdings Inc trades at $531.9 (market cap $15.31B). The key difference: Charter Communications Inc and Medpace Holdings Inc are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| CHTR | MEDP | |
|---|---|---|
Market Cap | $15.73B | $15.31B |
Sector | Media | Technology |
52-Week High | $398.11 | $620.59 |
52-Week Low | $125.54 | $308.88 |
Enterprise Value | $112.04B | $14.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $131.37, up 0.49% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The stock appears deeply undervalued with a P/E of 3.55 and EV/EBITDA of 5.3, supported by a 9.03% net income margin and strong cash flow. Recent news highlights potential strategic partnerships with SpaceX and acquisition interest from Comcast, driving investor optimism despite recent earnings misses.
The outlook for CHTR is cautiously optimistic, with significant upside potential based on analyst consensus targets near $196.20. Key opportunities include valuation discount, cash flow inflection, and strategic moves, while risks involve high debt levels, competitive pressures, and execution on subscriber growth. The stock's current level near support at $130 suggests a critical juncture for near-term direction.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
